Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.

@article{Montalescot2004AntiXaAR,
  title={Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.},
  author={Gilles Montalescot and Jean Philippe Collet and Marie Laure Tanguy and Annick Ankri and Laurent Payot and Raphaelle Dumaine and R{\'e}mi Choussat and Farzin Beygui and Vanessa Gallois and Dani{\`e}l Thomas},
  journal={Circulation},
  year={2004},
  volume={110 4},
  pages={392-8}
}
BACKGROUND Low-molecular-weight heparin (LMWH) is recommended in the treatment of unstable angina (UA)/non-ST-segment-elevation myocardial infarction (NSTEMI), but no relationship has ever been shown between anticoagulation levels obtained with LMWH treatment and clinical outcomes. METHODS AND RESULTS In all, 803 consecutive patients with UA/NSTEMI were treated with subcutaneous enoxaparin and were followed up for 30 days. The recommended dose of enoxaparin of 1 mg/kg BID was used throughout… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology

  • F Van de Werf, D Ardissino, A Betriu
  • Eur Heart J. 2003;24:28–66
  • 2003

Similar Papers

Loading similar papers…